ArticleFrontiers in immunology2022

Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes.

Paolo Del Barba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.